# BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

Source: https://onco.cc/trials/nct06793332/  
OnCo record `nct06793332` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC is a phase 2, interventional study registered as NCT06793332 by Fudan University, with a registry enrolment figure of 39 participants, started 2024-12-17 and due to reach its primary completion in 2026-01-31. Interventions recorded: Ivonescimab Combined With TROP2 ADC. Conditions listed: Triple-Negative Breast Cancer (TNBC); Brain Metastases. Triple-negative eligibility wording from the registry: "Patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed treatment with taxane drugs are included". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: BALISTA
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06793332
- Phase: 2
- Setting: Prospective, One-arm, Phase II Clinical Study of Ivoximab Combined With TROP2 ADC in the Treatment of Brain Metastases in Triple-negative Breast Cancer
- Sponsor: Fudan University
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT06793332: https://clinicaltrials.gov/study/NCT06793332

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06793332.json